PRM-151 is a recombinant form of Pentraxin-2, an endogenous human protein that actively works at the site of tissue damage, as a monocyte/macrophage differentiation factor and as an agonist with the potential to both prevent and reverse fibrosis. Pre-clinical and clinical data exist to support the investigation of PRM-151 in the treatment of fibrotic diseases. PRM-151 is administered intravenously. 

Learn more about PRM-151